- Home
- GDHG vs LPCN Comparison
GDHG vs LPCN Comparison
Compare GDHG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- LPCN
- Stock Information
- Founded
- GDHG 2008
- LPCN 1997
- Country
- GDHG China
- LPCN United States
- Employees
- GDHG N/A
- LPCN N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- LPCN Health Care
- Exchange
- GDHG Nasdaq
- LPCN Nasdaq
- Market Cap
- GDHG 19.4M
- LPCN 18.2M
- IPO Year
- GDHG 2023
- LPCN N/A
- Fundamental
- Price
- GDHG $6.70
- LPCN $3.11
- Analyst Decision
- GDHG
- LPCN Strong Buy
- Analyst Count
- GDHG 0
- LPCN 1
- Target Price
- GDHG N/A
- LPCN $8.00
- AVG Volume (30 Days)
- GDHG 32.9K
- LPCN 51.1K
- Earning Date
- GDHG 07-11-2025
- LPCN 11-06-2025
- Dividend Yield
- GDHG N/A
- LPCN N/A
- EPS Growth
- GDHG N/A
- LPCN N/A
- EPS
- GDHG N/A
- LPCN N/A
- Revenue
- GDHG $16,666,899.00
- LPCN $4,208,119.00
- Revenue This Year
- GDHG N/A
- LPCN N/A
- Revenue Next Year
- GDHG N/A
- LPCN N/A
- P/E Ratio
- GDHG N/A
- LPCN N/A
- Revenue Growth
- GDHG N/A
- LPCN N/A
- 52 Week Low
- GDHG $2.40
- LPCN $2.65
- 52 Week High
- GDHG $1,968.41
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- GDHG 43.05
- LPCN 54.39
- Support Level
- GDHG $6.36
- LPCN $3.03
- Resistance Level
- GDHG $7.70
- LPCN $3.21
- Average True Range (ATR)
- GDHG 0.52
- LPCN 0.18
- MACD
- GDHG -0.20
- LPCN 0.01
- Stochastic Oscillator
- GDHG 42.33
- LPCN 48.10
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.